DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,313,933 | -30.8% | 354,529 | -1.1% | 0.03% | -25.7% |
| Q2 2023 | $10,575,853 | +58.7% | 358,382 | +23.9% | 0.04% | +52.2% |
| Q1 2023 | $6,664,136 | -17.3% | 289,242 | -0.2% | 0.02% | -20.7% |
| Q4 2022 | $8,062,675 | -47.2% | 289,920 | -41.7% | 0.03% | -3.3% |
| Q3 2022 | $15,269,813 | +4.7% | 497,544 | +0.4% | 0.03% | +11.1% |
| Q2 2022 | $14,579,546 | +13.0% | 495,382 | +23.5% | 0.03% | +50.0% |
| Q1 2022 | $12,904,273 | +31.5% | 401,136 | +82.3% | 0.02% | -28.0% |
| Q4 2021 | $9,815,000 | -3.5% | 220,066 | +9.2% | 0.02% | -13.8% |
| Q3 2021 | $10,170,000 | -64.5% | 201,580 | -44.8% | 0.03% | -29.3% |
| Q2 2021 | $28,662,000 | +183.6% | 365,400 | +106.5% | 0.04% | +32.3% |
| Q1 2021 | $10,105,000 | -23.7% | 176,978 | +11.9% | 0.03% | -26.2% |
| Q4 2020 | $13,250,000 | +65.8% | 158,190 | -29.1% | 0.04% | +44.8% |
| Q3 2020 | $7,993,000 | -26.6% | 223,071 | -50.5% | 0.03% | +38.1% |
| Q2 2020 | $10,890,000 | +65.5% | 450,380 | +19.8% | 0.02% | +31.2% |
| Q1 2020 | $6,582,000 | – | 375,924 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |